Pharnext SA announced the signature of a strategic agreement with Tasly Pharmaceutical. This partnership includes the development of a new pipeline of synergistic combinations through a shared platform and the license of Pharnext's lead product for the Chinese market. The creation of a research and development Joint-Venture, owned 30% by Pharnext, to develop new combinations of molecules.

Programs will be pursued in several indications, primarily in cardiovascular and oncology therapeutic areas. Both companies will share their expertise: Pharnext in the development of synergistic combinations of drugs and Tasly in the use of traditional Chinese medicine wealth. Once the combination of molecules proof of concept is established in humans, commercialization rights will either be allocated to Pharnext and Tasly or licensed to third parties.

A licensing agreement for the development and commercialization by the joint venture of the drug candidate PXT3003 for Charcot-Marie-Tooth type 1A disease on the Chinese market.